PT  - JOURNAL ARTICLE
AU  - Andrew A Tester
AU  - Sheena Logan
AU  - Louisa Pollock
AU  - Allison McKie
TI  - Clenbuterol: a new toxic substance in paediatrics
AID  - 10.1136/bcr-2019-233180
DP  - 2020 Mar 01
TA  - BMJ Case Reports
PG  - e233180
VI  - 13
IP  - 3
4099  - http://casereports.bmj.com/content/13/3/e233180.short
4100  - http://casereports.bmj.com/content/13/3/e233180.full
SO  - BMJ Case Reports2020 Mar 01; 13
AB  - A 13-year-old girl presented to the emergency department with acute onset of chest pain, nausea and tremor. The patient denied drug ingestion, and urine toxicology was negative. ECG demonstrated sinus tachycardia, prolonged QTc (541 ms) and ST depression. Laboratory testing demonstrated metabolic acidosis, hypokalaemia, hypophosphataemia and hyperglycaemia. She was commenced on continuous cardiac monitoring and treated with intravenous fluids and electrolyte replacement. Presenting features and laboratory abnormalities resolved within 48 hours. The National Poisons Information Service and Clinical Biochemistry were integral to her management, advising the clinical team on the likeliest aetiology. Five weeks after discharge, urine toxicology, using mass spectrometry, identified clenbuterol. Clenbuterol is an oral β2-agonist with anabolic and lipolytic effects that is misused as a performance and image enhancing drug. Clinicians must be aware of the increasing availability of these drugs and their potential for causing harm in children and adolescents.